Kornimate/medical-research-clean huggingface dataset:
drug-coated coronary balloons in different clinical scenarios

Conditions: Coronary Arterial Disease (CAD)

Summary: coronary stents are the best treatment method ever accepted in the treatment of coronary artery stenoses. due to some limitations and complications of stent use, the operators tried to find new solutions. drug coated balloons (dcbs) have been accepted as a new method in the treatment of in-stent restenosis and small vessel disease. furthermore, they have been used in the treatment of de novo coronary lesions, chronic total occlusions and bifucation lesions. but data is limited in the short and long term success of dcbs in all these clinical scenarios. in our study we aimed to investigate the procedural success and short and long term outcomes of dcb use in different clinical scenarios.


Eligibility criteria:
inclusion criteria: * patients treated with drug coated balloons exclusion criteria: * patients treated with other than dcbs

Keywords: drug coted balloons coronary artery disease chronic total occlusions de novo lesions small vessel disease
transcatheter arterial chemoembolization with kmg microsphere treating advance-stage hepatocellular carinomas (tace-kmg)

Conditions: Carcinoma, Hepatocellular

Summary: the purpose of this study is to evaluate the effects of transcatheter arterial chemoembolization (tace) with kmg microsphere in treating hcc. and to determine which one is better,kmg microsphere or lipiodol?

the most important part of effect in tace is embolization .but there is no clinical trials on which one is better,kmg microsphere or lipiodol? what effect did chemo play in the tace treating hcc? which one is better,routine dose or low dose? experts in usa and japan had their own researches and standpoints.we think it is important to push a clinical trail to answer these problem.

Eligibility criteria:
inclusion criteria: * hepatocellular carinomas with diagnosis of pathology or cytology or consistent with china 2001 guideline of clinical diagnosis hepatocellular carinomas clinical stage（the barcelona liver clinic staging system,bclc b and c)，or can not receive surgical intervention * liver function:child-pugh a、b * pst 0-1（eastern cooperative oncology group performance score ,ecog） * lifespan≥6 months * first time to receive treatment * can accept the follow up * informed consent was gotten * the number of lesion ≤ 5 exclusion criteria: * pregnant or lactation woman * emotional disturbance * serious heart ,lung disfunction or serious diabetes mellitus * serious reactiveness infections;（exp:type b or c hepatitis） * liver function :child-pugh score c * thrombocyte\<6×109/l * diffuse hcc * widespread metastasis * serious atherosclerosis * acquired immunodeficiency syndrome;aids * thrombosis or thrombosis event in 6 months * renal inadequacy who need hemodialysis or peritoneal dialysis * with other tumors except basal cell carcinoma and carcinoma in situ of cervix * serious alimentary tract hemorrhage in 4 weeks

Keywords: hcc tace
effect of continued nutritional support at hospital discharge on mortality, frailty, functional outcomes and recovery

Conditions: Malnutrition

Summary: this study is to compare the sustained post-discharge nutritional support to reach individual energy and protein goals to usual care home nutrition in medical patients at nutritional risk.

malnutrition is a strong and independent long-term risk factor for mortality, rehospitalisation and functional decline, particularly in the elderly, polymorbid medical patient population. the randomized-controlled effect of early nutritional support on frailty, functional outcomes and recovery of malnourished medical inpatients trial (effort, lancet 2019) included 2028 patients in eight swiss hospitals and found that nutritional support during the inhospital stay reduces very efficiently the risk for complications and mortality with numbers needed to treat (nnt) of 23 and 37, respectively. yet, the nutritional intervention was not continued after hospital discharge of patients and long-term follow-up data of patients showed a lack of sustained effect of the initial nutritional support strategy. there is a current lack of trial data investigating whether long-term use of nutritional support has a sustained effect on clinical outcomes in this patient population. this study is to compare the continuous use of nutritional support with the use of approved oral nutritional supplements to reach protein and energy goals and to analyze whether medical patients at nutritional risk show a sustained benefit from long-term nutritional support after hospital discharge, and why and how nutritional support affects the course of disease from a mechanistic physio-pathological standpoint.

Eligibility criteria:
inclusion criteria: * informed consent as documented by signature * adult (age ≥18 years), medical patients * nutritional risk screening using the nutritional risk screening (nrs): total score ≥3 points consisting of ≥1 points for impairment of the nutritional status \[weight loss \>5% in 3 month or food intake of 50-75% in the last week before hospital admission\] plus ≥1 for the severity of the disease (i.e., cancer, chronic kidney disease, chronic heart failure, copd) and other chronic diseases according to the definition of the "national center for chronic disease prevention and health promotion": chronic diseases are defined broadly as conditions that last 1 year or more and require ongoing medical attention or limit activities of daily living or both . exclusion criteria: * after surgery * unable to ingest oral nutrition * need for long-term nutrition, * terminal condition * acute pancreatitis or acute liver failure * patients discharged to a nursing home * patients unlikely to comply with nutritional support treatment (e.g., dementia) * covid-hospitalisation requiring intensive care

Keywords: nutritional support oral nutritional supplements frailty mortality morbidity
inspiratory muscle training in covid-19 patients

Conditions: Covid19; Exercise

Summary: this study aims to investigate whether adjunctive inspiratory muscle training (imt) can enhance the benefits of pulmonary rehabilitation (pr) in patients with covid-19. 120 patients will be randomized into an interventional group (pr plus imt) and a control group (sham imt plus pr). improvement in quality of life, peak vo2 and ve/vco2 slope will be defined as a primary outcome. maximal inspiratory pressure, inspiratory muscle endurance, pulmonary function testing, severity of fatigue, cost-effectiveness and six minute walk test will be defined as the secondary outcomes.


Eligibility criteria:
inclusion criteria: to be eligible, participants must be: * over 18 years of age * confirmed covid-19 diagnosis * individuals that required hospitalization and either i) non-invasive respiratory support (cpap, high-flow oxygen catheter, non-breathing oxygen mask, or ii) invasive mechanical ventilation within three months of study recruitment. exclusion criteria: * pregnancy * dependence on others to perform activities of daily living during the month prior to the current icu admission (gait aids are acceptable) * documented cognitive impairment * proven or suspected spinal cord injury, or other neuromuscular diseases that will result in a permanent or prolonged weakness (not including icu acquired weakness) * severe neurological disease * death is deemed inevitable as a result of the current illness and either the patient or treating clinical or substitute decision-maker are not committed to full active treatment.

Keywords: respiratory function tests inspiratory muscle training
a comparison of accelerometers for measuring daily activity in sarcoid

Conditions: Sarcoidosis

Summary: this cross-over study of 12 patients with sarcoidosis will look at two different widely-used accelerometer devices. these devices are wrist worn and similar in size to a wrist-watch. they measure daily activity levels. the investigators hope to use one of these devices in the future within a randomised-controlled trial looking at using methylphenidate for the treatment of sarcoidosis-associated fatigue. in order to ensure that the investigators choose the ideal device the investigators wish to compare the geneactiv and actigraph gt3x devices. participants will be required to wear the devices for 7 days each, with 6 patients beginning with the geneactiv device and changing to the actigraph device after 7 days, the remaining 6 participants starting with the actigraph before changing to the geneactiv. patients will complete a short exit questionnaire about their experience with the devices and their preference. the best device will be determined by both patient preference and reliability of collecting data.

this will be a small comparator study comparing two devices (geneactiv original and actigraph gt3x) in 12 patients with sarcoidosis. participants wear one device for 7 days before returning the device, and wear the second device to wear for a further 7 day period. each participant will wear the devices for 24 hours throughout the measurement period. the devices will be worn in a random order, randomised using sealed envelopes. they will be advised not to remove the devices during the 7 day monitoring period, with the exception of the gt3x which should be removed if the participant is bathing or swimming (they are able to shower). when each device is returned the participants will be asked to complete an exit questionnaire on their experience with the device. before the participants wear the devices they will be asked to complete a short question regarding how tired/fatigued they feel. the devices will be worn on the participant's non-dominant wrist. they will wear both devices in a random order (determined by randomisation at the start of the trial with regards to which device will be worn first). six participants will start with the geneactiv device and six will begin with the actigraph gt3x device. the device order will be chosen randomly based upon a random number sequence generated in microsoft excel and placed in envelopes numbered 1 to 12.

Eligibility criteria:
inclusion criteria: 1. male or female aged over 18 2. diagnosed with sarcoidosis by either; biopsy confirming non-caseating granulomas consistent with sarcoidosis, or multi-disciplinary interstitial lung disease meeting diagnosis of sarcoidosis. 3. ambulatory patient (not wheelchair or bed-bound) 4. able to provide written informed consent exclusion criteria: 1. unable to provide informed consent.

Keywords: sarcoidosis daily activity exercise accelerometer
lateral neck sentinel lymph node biopsy(lslnb)in ptc

Conditions: Thyroid Neoplasm

Summary: objective: to investigate the incidence of lateral neck node occult metastasis and to show the usefulness of sentinel lymph node biopsy (slnb) in the detection of lateral neck node metastasis in thyroid carcinoma, the investigators used a radioisotope to detect the sentinel lymph node. summary background data: although occult lymph node metastasis to the lateral neck compartment is common in papillary thyroid carcinoma, the incidence and patterns of lateral neck node metastasis in papillary carcinoma are not known.

on the day of the operation, patients underwent preoperative lymphoscintigraphy after the intratumoral injection of a tc-99m phytate 1 mci in 0.1-0.2 ml 0.9% nacl under ultrasonographic guidance. total thyroidectomy or lobectomy with central neck dissection preceded sln detection to avoid interference by primary tumor radioactivity. after total thyroidectomy or lobectomy, the dissections were performed toward the internal jugular chain beneath the sternocleidomastoid muscle. a handheld, collimated gamma probe and lymphoscintigraphy were used to scan the lateral compartments (through skin and under the scm) for "radioactive" lymph nodes. removed slns were submitted immediately for frozen biopsy. if any of the slns were positive for metastasis on the frozen sections, mrnd was performed immediately. in cases for which the frozen section was negative but the final pathology report detailed microscopic positivity in the lateral sentinel nodes, rai ablations were performed without additional mrnd.

Eligibility criteria:
inclusion criteria: * cases with tumors larger than 1 cm in size or with suspicious central neck node metastasis in papillary thyroid cancer exclusion criteria: * the patient with definite metastatic lymph node in lateral neck compartment
molecular and cellular analysis of breast cancer

Conditions: Breast - Female; Breast - Male

Summary: the purpose of the study is to investigate the different types and subtypes of cells found in breast tumors. the investigators will do this using a variety of molecular analysis tools that may allow for improved tests. the different types of cells in breast cancer impacts the way individuals respond to various treatments.


Eligibility criteria:
inclusion criteria: 1. histologically proven diagnosis of breast cancer or a carcinoma of unknown primary consistent with the presentation of a primary breast malignancy. 2. 18 years of age or older. 3. ability to understand and the willingness to sign a written informed consent do exclusion criteria: * none
effect of beta3-adrenoceptor agonist on patients with overactive bladder and as a urinary biomarker

Conditions: Overactive Bladder Syndrome; Detrusor Overactivity

Summary: about one to two million women in taiwan suffers from overactive bladder (oab). the most commonly used anti-muscarinic drugs have a high rate of side effects. while beta-3 adrenoceptor agonist, mirabegron, has far fewer side effects, there are no consensus on whether it can be used as first-line treatment. the investigator's preliminary study showed that the concentration of beta-3 adrenoceptor in the urine of oab patients is higher than that in the normal control group, so comparing urinary beta-3 adrenoceptor concentration of oab patients before and after treatment may be used as a biomarker of therapeutic effectiveness. the results of this study will be of great help in understanding the effectiveness of mirabegron and formulating oab treatment plans.


Eligibility criteria:
inclusion criteria: * diagnosis compatible with 2002 ics for overactive bladder syndrome * symptoms persisted for more than 3 months * completed pre-treatment urodynamic study * has plans for treatment with mirabegron or solifenacin due to clinical symptoms * patient is willing to cooperate with study including follow up and complete questionnaire surveys exclusion criteria: * has stress urinary incontinence * pelvic organ prolapse * interstitial cystitis * constipation * gastroesophageal reflux disease * prior failed medical treatment for overactive bladder syndrome * uncontrolled hypertension * glaucoma * currently pregnant * using other medications for overactive bladder syndrome

Keywords: overactive bladder syndrome mirabegron beta3-adrenoceptor agonist detrusor overactivity urodynamics biomarker
study of subcutaneous immune globulin in patients requiring igg replacement therapy

Conditions: Common Variable Immunodeficiency; X-linked Agammaglobulinemia; Autosomal Recessive Agammaglobulinemia

Summary: the objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of igpro20 in patients with primary humoral immunodeficiency (pid).

this study consisted of a 12-week wash-in/wash-out period followed by a 28-week efficacy period. during the 28-week efficacy period, subjects visited the study site at least every 4 weeks for efficacy and safety evaluations and additionally recorded details regarding igpro20 dose and certain aspects of efficacy and safety in a diary. pharmacokinetic (pk) parameters were assessed in a sub-group of subjects during 1 treatment interval at steady-state (week 28 ± 1).

Eligibility criteria:
inclusion criteria: * subjects with primary humoral immunodeficiency, namely with a diagnosis of common variable immunodeficiency (cvid) as defined by the pan-american group for immunodeficiency (pagid) and european society for immunodeficiencies (esid), x-linked agammaglobulinemia (xla) as defined by pagid and esid, or autosomal recessive agammaglobulinemia * chest x-ray or ct scan obtained within 1 year prior to enrolment exclusion criteria: * newly diagnosed pid, i.e. subjects who have not previously received immunoglobulin replacement therapy * ongoing serious bacterial infection at the time of screening * malignancies of lymphoid cells such as lymphocytic leukemia, non-hodgkin's lymphoma and immunodeficiency with thymoma * allergic or other severe reactions to immunoglobulins or other blood products associated with high anti-iga additional criteria may apply and examination by an investigator is required to determine eligibility.

Keywords: subcutaneous immune globulin scig
determination of specific biomarkers of acute attack of angioedema within pediatric population

Conditions: Hereditary Angioedema; Healthy Volunteers

Summary: in emergency room, this is crucial to diagnose an acute attack of hereditary angioedema (hae) to quickly provide the efficient treatment. currently, there is no specific biomarker for acute attack of bradykinin-mediated angioedema to help clinicians for patient care. however, previous works are carried out for that purpose. all the potential candidate biomarkers must be validated in prospective studies to estimate their specificity and sensitivity values, and to understand their potential utility in patient care. the main goal of this clinical trial is to estimate the diagnostic value of ve-cadherin in pediatric population, for the differential diagnosis between hae crisis and angioedema resulting of mast cell activation crisis (the main differential diagnosis of hae).


Eligibility criteria:
inclusion criteria: for hae: patient with a documented diagnosis of hae: * type i (from an antigenic deficiency of the c1 esterase inhibitor) or type ii (from a functional deficiency of the c1 esterase inhibitor). the existence of a mutation in serping1 was not necessary for the inclusion * hae with normal c1-inh (ex type iii) with a required mutation in fxii gene or with a typical family history of hae diagnosed by a specialized physician belonging to creak network. for ae resulting of mast cell activation: a documented diagnosis of ae resulting of mast cell activation included: * mastocytosis, * chronic spontaneous urticaria, * acute urticaria after exposure of allergen during allergy challenge tests, * mast cell activation syndrome. for the control group: * composed of patients who presented a stabilized disease (that was not infectious, not auto-inflammatory or inflammatory disease and without implication of endothelial cells). exclusion criteria: * over 18 years or under 1 year. * diagnosis of hae with a normal c1 esterase inhibitor or ae of unknown aetiology. * patients with hae who received an acute attack treatment before the blood sample (the c1 esterase inhibitor concentrate or a bradykinin b2 receptor antagonist); patients with hae who received a prophylactic treatment (danazol). * patients who were treated by omalizumab or corticosteroid treatment.
cognitive function and health-related quality of life after neuro-intensive care

Conditions: Acute Brain Injury; Cognitive Dysfunction; Delirium; Sepsis; Post-traumatic Amnesia; Health-related Quality of Life

Summary: the study will provide information on cognitive impairment and health related quality of life in patients surviving 12 months after acute brain injury, generate a hypothesis of useful variables to predict cognitive impairment or low levels of hrqol, and potentially inform interventions for the prevention and treatment of cognitive impairment following neuro-icu stay.

the aim is to 1) measure the frequency and extent of cognitive impairment after acute brain injury at six and 12-months after neuro-intensive care unit (icu) admission 2) explore the association between cognitive impairment at six and 12 months after icu admission with the following potential risk factors: duration of icu delirium (days), duration of sepsis (days), duration of post traumatic amnesia (days) and the severity of brain injury (initial glasgow coma scale , 3) describe health related quality of life, functional disability and frailty at six and 12 after icu admission and 4) explore the association between the functional disability, frailty and health-related quality of life at 12 months after icu admission

Eligibility criteria:
inclusion criteria: * traumatic brain injury * spontaneous intracranial hemorrhage * ischemic stroke * an anticipated stay in the neuro-icu for 48 hours or longer. exclusion criteria: * persistent coma defined as richmond agitation-sedation scale (rass) -5 to -3 throughout the neuro-icu stay * congenital brain injury * suspected pre-existing cognitive impairment (informant questionnaire on cognitive decline in the elderly (iqcode): 3.3 or more) (regardless of cause) * permanent residence outside denmark * inability to communicate in danish

Keywords: acute brain injury after intensive care unit care
clinical outcomes of cad/cam single-retainer monolithic zirconia ceramic resin-bonded fixed dentures bonded with two different resin cements

Conditions: Denture, Partial, Fixed, Resin-Bonded; Tooth Loss / Rehabilitation; Resin Cements

Summary: congenitally missing tooth is one of the most common anomalies in human dentition. the treatment options of lateral incisor agenesis are closing the space with orthodontic treatment, implant treatment, conventional fixed dental prosthesis (fdps) and resin-bonded fixed dentures (rbfds). rbfds are used frequently for single tooth absence in the anterior region due to their minimal invasive properties, high clinical success and patient satisfaction. with the development of new and stronger materials, rbfds with metal framework have been replaced by glass ceramic, lithium disilicate, fiber-reinforced composite (frc) and zirconia. the aim of this study is to evaluate the clinical performance of cad/cam single-retainer monolithic zirconia ceramic rbfds which cemented with two different resin cements.

the aim of this study is to evaluate the clinical performance of cad/cam single-retainer monolithic zirconia ceramic rbfds which cemented with two different resin cements. the project includes 20 patients. most of the patients have been recruited from the istanbul medipol university dental clinics in istanbul. the patients were selected from individuals who have unilateral or bilateral congenitally missing maxillary lateral teeth and wanted to be treated a restoration or undergoing orthodontic treatment. after giving their consent to take part in the study no preparations were made on abutment teeth for rbfds. digital impressions were taken with an intraoral digital scanner. the rbfds were designed using a cad software, milled and presintered zirconia blocks (katanatm zirconia ht, kuraray noritake dental inc, tokyo, japan). rbfd was adhesively bonded to abutment teeth with one of the two different resin cements (panavia f2.0 or panavia v5). the control procedure is: the restoration is evaluated according to presence of mobility or debonding and fracture at the connector area. gingival harmony and periodontal tissues around the restorations were also examined. mobility of the abutment tooth was checked in the clinical examination and alveolar bone was examined with periapical x-ray. the controls will take place after two weeks, one year, two years, three years and five years.

Eligibility criteria:
inclusion criteria: * participating in the study voluntarily * horizontal mobility of central incisors ≤1 mm * central incisors with healthy alveolar bone * 1-1,5 mm overjet * having a good anterior guidance exclusion criteria: * patients with gingivitis or periodontitis poor oral hygiene central incisors with endodontic treatment or periapical disease central teeth with large fillings or loss of dental structure on the cementation surface bad oral habits patients with clinical symptoms of bruxism